Novartis AG
NOT
Company Profile
Business description
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Contact
Lichtstrasse 35
Basel4056
CHET: +41 613241111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
75,883
Stocks News & Analysis
stocks
Most popular shares in SMSFs
With data showing the continued rise of SMSFs, we explore the top stock picks of individual investors
stocks
Will China strong arm BHP into lower iron ore prices?
Allegations that the Chinese government told steel mills to stop buying from BHP shake markets.
stocks
Chart of the Week: Where Morningstar sees attractive dividend yields in 26/27
Charts from the Australian Dividend Outlook show the sectors where they are abundant.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,264.30 | 8.50 | 0.09% |
| CAC 40 | 7,918.00 | 123.36 | -1.53% |
| DAX 40 | 24,241.46 | 369.79 | -1.50% |
| Dow JONES (US) | 45,479.60 | 878.82 | -1.90% |
| FTSE 100 | 9,427.47 | 81.93 | -0.86% |
| HKSE | 26,290.32 | 462.27 | -1.73% |
| NASDAQ | 22,204.43 | 820.20 | -3.56% |
| Nikkei 225 | 48,088.80 | 491.64 | -1.01% |
| NZX 50 Index | 13,467.26 | 103.60 | -0.76% |
| S&P 500 | 6,552.51 | 182.60 | -2.71% |
| S&P/ASX 200 | 8,958.30 | 9.20 | 0.10% |
| SSE Composite Index | 3,897.03 | 36.94 | -0.94% |